专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2009138511A1 LONG-ACTING Y2 AND/OR Y4 RECEPTOR AGONISTS 审中-公开
标题翻译：长期行动Y2和/或Y4受体激素
公开(公告)号：WO2009138511A1
公开(公告)日：2009-11-19
申请号：PCT/EP2009/055989
申请日：2009-05-18
申请人： NOVO NORDISK A/S , ØSTERGAARD, Søren , KNUDSEN, Sanne Møller , SPETZLER, Jane , JØRGENSEN, Rasmus , KOFOED, Jacob
发明人： ØSTERGAARD, Søren , KNUDSEN, Sanne Møller , SPETZLER, Jane , JØRGENSEN, Rasmus , KOFOED, Jacob
IPC分类号： C07K14/575 , A61K38/17
CPC分类号： C07K14/575 , A61K47/542
摘要： The present invention relates to a PYY or PP peptide derivative or analogue thereof derivatised with one or more serum albumin binding side chains comprising a dis-tal tetrazole or carboxylic acid group. Moreover, the invention relates to compositions hereof and methods of treatment of conditions responsive to Y receptor modulation.
摘要翻译：本发明涉及用包含四唑或羧酸基团的一种或多种血清白蛋白结合侧链衍生的PYY或PP肽衍生物或其类似物。此外，本发明涉及本发明的组合物和治疗对Y受体调节作用的病症的方法。

2. 发明申请

WO2011058165A1 LONG-ACTING Y2 RECEPTOR AGONISTS 审中-公开
标题翻译：长期行动Y2受体激素
公开(公告)号：WO2011058165A1
公开(公告)日：2011-05-19
申请号：PCT/EP2010/067454
申请日：2010-11-15
申请人： NOVO NORDISK A/S , KOFOED, Jacob , YNDDAL, Lars , ØSTERGAARD, Søren , JØRGENSEN, Rasmus , NIELSEN, Flemming Sejer , NILSSON, Cecilia , THOMSEN, Jens Kaalby
发明人： KOFOED, Jacob , YNDDAL, Lars , ØSTERGAARD, Søren , JØRGENSEN, Rasmus , NIELSEN, Flemming Sejer , NILSSON, Cecilia , THOMSEN, Jens Kaalby
IPC分类号： A61K38/22 , A61K47/48 , C07K14/575
CPC分类号： C07K14/575 , A61K47/542
摘要： The present invention relates to PYY derivatives comprising a serum albumin binding side chain, wherein said derivative has a half-life of at least 7 hours as determined by Assay (IV) described herein as well as compositions comprising said derivative and its use in therapy.
摘要翻译：本发明涉及包含血清白蛋白结合侧链的PYY衍生物，其中所述衍生物通过本文所述的测定（IV）测定的半衰期为至少7小时，以及包含所述衍生物的组合物及其在治疗中的用途。

3. 发明申请

WO2011033068A1 LONG-ACTING Y2 RECEPTOR AGONISTS 审中-公开
标题翻译：长期行动Y2受体激素
公开(公告)号：WO2011033068A1
公开(公告)日：2011-03-24
申请号：PCT/EP2010/063707
申请日：2010-09-17
申请人： NOVO NORDISK A/S , KOFOED, Jacob , OLSEN, Jørgen , ØSTERGAARD, Søren , JØRGENSEN, Rasmus
发明人： KOFOED, Jacob , OLSEN, Jørgen , ØSTERGAARD, Søren , JØRGENSEN, Rasmus
IPC分类号： A61K38/22 , A61K47/48 , C07K14/575
CPC分类号： C07K14/575 , A61K38/00
摘要： The present invention relates to PYY analogues or derivatives thereof comprising at least one alteration selected from the group consisting of substitutions, insertions, deletions and modifications and optionally a serum albumin binding side chain comprising an alkyl chain with at least 14 carbon atoms. Moreover, the invention relates to compositions hereof and methods of treatment of conditions responsive to Y2 receptor modulation.
摘要翻译：本发明涉及包含至少一种选自取代，插入，缺失和修饰的改变的PYY类似物或其衍生物，以及任选地包含具有至少14个碳原子的烷基链的血清白蛋白结合侧链。此外，本发明涉及本发明的组合物和治疗对Y2受体调节作用的病症的方法。

4. 发明申请

WO2013178490A1 PANCREATIC POLYPEPTIDE COMPOUNDS AND USE 审中-公开
标题翻译： PANCREATIC POLYPEPTIDE化合物和用途
公开(公告)号：WO2013178490A1
公开(公告)日：2013-12-05
申请号：PCT/EP2013/060259
申请日：2013-05-17
申请人： NOVO NORDISK A/S
发明人： JØRGENSEN, Rasmus , ØSTERGAARD, Søren , YNDDAL, Lars , NIELSEN, Flemming, Seier
IPC分类号： C07K14/575 , A61K38/22
CPC分类号： C07K14/575 , A61K38/00 , A61K38/2271 , C07K14/57545
摘要： The invention relates to novel use of Pancreatic Polypeptides as well as novel Pancreatic Polypeptides and compositions thereof. Such peptides can be used in treating or preventing conditions responsive to Y4 and/or Y5 receptor activation, such as cachexia.
摘要翻译：本发明涉及胰腺多肽的新用途以及新型胰腺多肽及其组合物。这样的肽可用于治疗或预防对Y4和/或Y5受体活化如恶病质有反应的病症。

5. 发明申请

WO2003056329A3 USE OF A SIGNAL TRANSDUCTION COMPLEX IN DRUG DISCOVERY PROCESSES 审中-公开
公开(公告)号：WO2003056329A3
公开(公告)日：2003-07-10
申请号：PCT/DK2002/000901
申请日：2002-12-20
申请人： 7TM PHARMA A/S , SCHWARTZ, Thue, W. , LANGE, Birgitte, Holst , HEYDORN, Arne , JØRGENSEN, Rasmus
发明人： SCHWARTZ, Thue, W. , LANGE, Birgitte, Holst , HEYDORN, Arne , JØRGENSEN, Rasmus
IPC分类号： G01N33/50
摘要： A drug discovery process for identification of a ligand that is able to bind to a biological target molecule, the process comprising a) constructing a signal transduction complex comprising a biological target molecule, one or more downstream effector molecules and, optionally, an adaptor protein, and b) contacting the ligand with the signal transduction complex, and c) measuring any effect resulting from a signal transduction process relating to the biological target molecule and one or more of the downstream effector molecules. A drug discovery process, wherein the signal transduction complex comprises a first component comprising a biological target molecule, a second component comprising one or more adaptor protein(s) and a third component comprising one or more downstream effector molecule(s), wherein each of the components recognizes or binds at least one of the other components to effect a signal transduction process, and wherein at least one of the components has been modified to contain one or more domains and/or one or more recognition motifs.

6. 发明申请

WO2003056329A2 USE OF A SIGNAL TRANSDUCTION COMPLEX IN DRUG DISCOVERY PROCESSES 审中-公开
标题翻译：在药物发现过程中使用信号传导复合物
公开(公告)号：WO2003056329A2
公开(公告)日：2003-07-10
申请号：PCT/DK2002/000901
申请日：2002-12-20
申请人： 7TM PHARMA A/S , SCHWARTZ, Thue, W. , LANGE, Birgitte, Holst , HEYDORN, Arne , JØRGENSEN, Rasmus
发明人： SCHWARTZ, Thue, W. , LANGE, Birgitte, Holst , HEYDORN, Arne , JØRGENSEN, Rasmus
IPC分类号： G01N33/50
CPC分类号： C12Q1/00 , G01N33/50
摘要： A drug discovery process for identification of a ligand that is able to bind to a biological target molecule, the process comprising a) constructing a signal transduction complex comprising a biological target molecule, one or more downstream effector molecules and, optionally, an adaptor protein, and b) contacting the ligand with the signal transduction complex, and c) measuring any effect resulting from a signal transduction process relating to the biological target molecule and one or more of the downstream effector molecules. A drug discovery process, wherein the signal transduction complex comprises a first component comprising a biological target molecule, a second component comprising one or more adaptor protein(s) and a third component comprising one or more downstream effector molecule(s), wherein each of the components recognizes or binds at least one of the other components to effect a signal transduction process, and wherein at least one of the components has been modified to contain one or more domains and/or one or more recognition motifs.
摘要翻译：用于鉴定能够结合生物靶分子的配体的药物发现方法，所述方法包括构建包含生物靶分子，一个或多个下游效应分子和任选的衔接蛋白的信号转导复合物，和 b使配体与信号转导复合体接触，以及c测量由与生物靶分子和一个或多个下游效应分子相关的信号转导过程产生的任何影响。一种药物发现方法，其中所述信号转导复合物包含包含生物靶分子的第一组分，包含一种或多种衔接蛋白的第二组分和包含一种或多种下游效应分子的第三组分，其中每种组分识别或结合于影响信号转导过程的其它组分中的至少一种，并且其中至少一种组分已被修饰以含有一个或多个结构域和/或一个或多个识别基序。

7. 发明申请

WO2003055914A3 MODIFIED RECEPTORS FOR THE DISCOVERY OF THERAPEUTIC LIGANDS 审中-公开
公开(公告)号：WO2003055914A3
公开(公告)日：2003-07-10
申请号：PCT/DK2002/000900
申请日：2002-12-20
申请人： 7TM PHARMA A/S , SCHWARTZ, Thue, W. , MARTINI, Lene , HEYDORN, Arne , JØRGENSEN, Rasmus
发明人： SCHWARTZ, Thue, W. , MARTINI, Lene , HEYDORN, Arne , JØRGENSEN, Rasmus
IPC分类号： C07K14/705
摘要： A drug discovery method for selecting a compound selected from the group consisting of a small organic substance, a biopharmaceutical and an antibody or part thereof. The method comprises the steps of i) expressing one or more receptors on a cell membrane, such as, e.g., an exterior cell surface of a cell, ii) contacting one or more expressed receptors with a test compound or a selection of test compounds (libraries) and iii) selecting one or more compounds based on its ability to bind one or more receptors. The step of expressing the one or more receptors comprises capturing one or more receptors on the exterior cell surface in a conformation that predominantly enables binding or interaction with a ligand, and the conformation that predominantly enables binding or interaction with a ligand is provided by modification of one or more receptors by a method comprising at least one of the following: (a) fusion with any protein which keeps the receptor in the desired conformation such as, e.g. an arrestin, a modified arrestin, a G-protein or a modified G-protein, (b) site-directed mutagenesis, and (c) deletion. The receptors may be captured on the exterior cell surface by at least one of the following: (d) interaction of the receptor with a scaffolding protein, optionally, with a scaffolding protein network and (e) means for blocking receptor internalization, e.g. by co-expression of a mutated dynamin or a modified arrestin or by use of chemicals such as, e.g., sucrose and/or Tris.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式